Regeneron Reports Phase 3 extension Data for Enfortumab vedotin in Esophageal cancer

Regeneron today announced Phase 3 extension results for enfortumab vedotin in patients with esophageal cancer. The study demonstrated that enfortumab vedotin demonstrates safety and tolerability compared to standard of care or placebo. These results provide important insights into the treatment of esophageal cancer and support the continued development of enfortumab vedotin in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.